FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155234088> ?p ?o ?g. }

• W2155234088 abstract "Abstract Background Diabetes is associated with a higher risk for adverse cardiovascular outcomes. To improve the health outcomes of patients with type 2 diabetes (T2DM), the American Diabetes Association (ADA) recommended target goals for the improvement of glycemic control and the reduction of cardiovascular risk factors associated with the disease. This retrospective analysis calculated the absolute benefit increase (ABI) of using exenatide once weekly (QW), a glucagon-like peptide-1 (GLP-1) receptor agonist, vs an oral glucose-lowering medication or insulin glargine to achieve ADA-recommended goals. The number needed to treat (NNT) to achieve these goals was also calculated and provides a useful clinical metric for comparing potential therapies from different drug classes. Methods Patient data from three double-blind or open label, 26-week, randomized, controlled trials were retrospectively analyzed separately. ABI and NNT were calculated by comparing the percentage of patients treated with exenatide QW (N = 641) vs metformin (N = 246), sitagliptin (N = 329), pioglitazone (N = 328), or insulin glargine (N = 223), who achieved a single glycemic, weight, blood pressure, or lipid goal or a composite of these recommended goals, during the DURATION-2, -3, and -4 clinical trials. Results Significant ABIs favoring exenatide QW over all four glucose-lowering medications were observed for at least one HbA1c glycemic goal. NNTs of 4 and 5 were calculated when exenatide QW was compared to sitagliptin for attaining HbA1c goals of <7.0% and ≤6.5%, respectively. Additionally, significantly more patients using exenatide QW compared to sitagliptin, pioglitazone, or insulin glargine attained the composite goal of HbA1c <7% or ≤6.5%, without weight gain or hypoglycemia. Exenatide QW was also favored over sitagliptin and insulin glargine for the achievement of the composite goals of HbA1c <7% (or ≤6.5%), systolic blood pressure <130 mm Hg, and low-density lipoprotein <2.59 mmol/L. For most goals, exenatide QW and metformin had similar effects in treatment naïve patients. Conclusions This analysis assessed the between-therapy differences in achieving therapeutic goals with therapies commonly used for glycemic control in patients with T2DM. In clinical trials, exenatide QW assisted more patients in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone, or insulin glargine. Trial registration NCT00637273 , NCT00641056 , NCT00676338" @default.
• W2155234088 created "2016-06-24" @default.
• W2155234088 creator A5010846329 @default.
• W2155234088 creator A5062877723 @default.
• W2155234088 creator A5071962255 @default.
• W2155234088 creator A5089249621 @default.
• W2155234088 creator A5090820164 @default.
• W2155234088 date "2013-03-23" @default.
• W2155234088 modified "2023-10-15" @default.
• W2155234088 title "Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals" @default.
• W2155234088 cites W1526927233 @default.
• W2155234088 cites W1568648090 @default.
• W2155234088 cites W1752045965 @default.
• W2155234088 cites W1982900907 @default.
• W2155234088 cites W1984740259 @default.
• W2155234088 cites W1989633984 @default.
• W2155234088 cites W1993821714 @default.
• W2155234088 cites W1995436055 @default.
• W2155234088 cites W1996134888 @default.
• W2155234088 cites W2010033044 @default.
• W2155234088 cites W2011499650 @default.
• W2155234088 cites W2017766892 @default.
• W2155234088 cites W2029084557 @default.
• W2155234088 cites W2043900831 @default.
• W2155234088 cites W2057364294 @default.
• W2155234088 cites W2060476230 @default.
• W2155234088 cites W2072691447 @default.
• W2155234088 cites W2076573528 @default.
• W2155234088 cites W2078089300 @default.
• W2155234088 cites W2083357334 @default.
• W2155234088 cites W2083415436 @default.
• W2155234088 cites W2096739965 @default.
• W2155234088 cites W2107949845 @default.
• W2155234088 cites W2111149452 @default.
• W2155234088 cites W2111824270 @default.
• W2155234088 cites W2123946565 @default.
• W2155234088 cites W2138077952 @default.
• W2155234088 cites W2139485303 @default.
• W2155234088 cites W2139634859 @default.
• W2155234088 cites W2139713364 @default.
• W2155234088 cites W2142400535 @default.
• W2155234088 cites W2152984355 @default.
• W2155234088 cites W2158778171 @default.
• W2155234088 cites W2162934281 @default.
• W2155234088 cites W2164763907 @default.
• W2155234088 cites W2171294019 @default.
• W2155234088 cites W2188846692 @default.
• W2155234088 cites W2337454357 @default.
• W2155234088 cites W2769264260 @default.
• W2155234088 cites W4250936128 @default.
• W2155234088 cites W4292528167 @default.
• W2155234088 doi "https://doi.org/10.1186/1475-2840-12-48" @default.
• W2155234088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3622579" @default.
• W2155234088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23522121" @default.
• W2155234088 hasPublicationYear "2013" @default.
• W2155234088 type Work @default.
• W2155234088 sameAs 2155234088 @default.
• W2155234088 citedByCount "21" @default.
• W2155234088 countsByYear W21552340882013 @default.
• W2155234088 countsByYear W21552340882014 @default.
• W2155234088 countsByYear W21552340882015 @default.
• W2155234088 countsByYear W21552340882016 @default.
• W2155234088 countsByYear W21552340882017 @default.
• W2155234088 crossrefType "journal-article" @default.
• W2155234088 hasAuthorship W2155234088A5010846329 @default.
• W2155234088 hasAuthorship W2155234088A5062877723 @default.
• W2155234088 hasAuthorship W2155234088A5071962255 @default.
• W2155234088 hasAuthorship W2155234088A5089249621 @default.
• W2155234088 hasAuthorship W2155234088A5090820164 @default.
• W2155234088 hasBestOaLocation W21552340881 @default.
• W2155234088 hasConcept C126322002 @default.
• W2155234088 hasConcept C134018914 @default.
• W2155234088 hasConcept C2777180221 @default.
• W2155234088 hasConcept C2778384471 @default.
• W2155234088 hasConcept C2779284873 @default.
• W2155234088 hasConcept C2779306644 @default.
• W2155234088 hasConcept C2779920387 @default.
• W2155234088 hasConcept C2780323712 @default.
• W2155234088 hasConcept C2780473172 @default.
• W2155234088 hasConcept C2780533449 @default.
• W2155234088 hasConcept C2780668416 @default.
• W2155234088 hasConcept C555293320 @default.
• W2155234088 hasConcept C71924100 @default.
• W2155234088 hasConcept C98274493 @default.
• W2155234088 hasConceptScore W2155234088C126322002 @default.
• W2155234088 hasConceptScore W2155234088C134018914 @default.
• W2155234088 hasConceptScore W2155234088C2777180221 @default.
• W2155234088 hasConceptScore W2155234088C2778384471 @default.
• W2155234088 hasConceptScore W2155234088C2779284873 @default.
• W2155234088 hasConceptScore W2155234088C2779306644 @default.
• W2155234088 hasConceptScore W2155234088C2779920387 @default.
• W2155234088 hasConceptScore W2155234088C2780323712 @default.
• W2155234088 hasConceptScore W2155234088C2780473172 @default.
• W2155234088 hasConceptScore W2155234088C2780533449 @default.
• W2155234088 hasConceptScore W2155234088C2780668416 @default.
• W2155234088 hasConceptScore W2155234088C555293320 @default.
• W2155234088 hasConceptScore W2155234088C71924100 @default.
• W2155234088 hasConceptScore W2155234088C98274493 @default.
• W2155234088 hasIssue "1" @default.
• W2155234088 hasLocation W21552340881 @default.

• next